Eli Lilly & Co. will only work with telehealth firms that agree to stop selling copycat versions of weight-loss drugs, diminishing the likelihood of a partnership with one most visible players in the ...

Lastly, the researchers observed that while patients who discontinued obesity medications lost significantly less weight ...

Novo Nordisk ( NVO 6.12%) stock, maker of the blockbuster GLP-1 agonist weight-loss drugs Ozempic and Wegovy, jumped a lucky ...

Novo Nordisk's Q1 showed robust sales/EPS growth, fueled by soaring GLP-1 demand in a multi-billion dollar market. Read why I ...

Teens are being prescribed Ozempic more than ever before — and some doctors are worried about what the trend could mean.

Hims & Hers Health is betting that the cash-pay market for weight-loss drugs will drive up customer demand although some ...

In what Guggenheim Partners called one of Metsera’s “critical program milestones” this year, its ultra-long-acting amylin ...

“With the semaglutide shortage declared over, Hims now has to transition its model to generate growth from other products ...

A new gene risk score, informed by machine learning, can predict weight-loss outcomes after Roux-en-Y gastric bypass surgery.

Novo Nordisk's popular weight-loss and diabetes drugs Wegovy and Ozempic may in very rare cases cause a serious eye condition ...

After reviewing several large epidemiological studies, clinical trial and in-market data, EMA’s Pharmacovigilance Risk Assessment Committee has concluded non-anterior ischemic optic neuropathy is a ...